The Division of Gastrointestinal (GI) and Liver Pathology is led by Dr. Wendy Frankel, and the other faculty members include Drs. William Marsh, Martha Yearsley and James Liu. Dr. Liu joined the division after completing both Cytopathology and GI Pathology Fellowships at OSU. The division started a fellowship in July of 2006 and continues to attract high quality fellows. Our volume continues to increase as new GI oncologic surgeons and gastroenterologists have already joined our team. Our division is actively involved in translational research in several areas; the most active include colorectal, hepatocellular, and pancreas carcinoma. Collaborations with Cancer Genetics and Dr. Albert de la Chapelle are at the forefront of our research. After a multiyear project involving 1500 colorectal carcinoma and greater than 500 endometrial carcinoma patients, we published influential articles in the New England Journal of Medicine and Cancer Research on Lynch Syndrome. These articles suggest ways to screen for Lynch Syndrome in colorectal and endometrial carcinoma patients that may alter the way these individuals are evaluated. With the support of Oncologic Surgery, Oncology and Cancer Genetics, we routinely screen colorectal carcinoma patients at OSU to evaluate for microsatellite instability and Lynch Syndrome. Other centers across the nation are adopting this practice, some with our assistance, and we are considered one of the leading centers for this initiative. Other publications resulting from this study include papers in Cancer Research and The Journal of Clinical Oncology. We continue to work closely with Cancer Genetics to constantly re-evaluate ways to screen our patients. There is currently great interest in using the results of these tests to help guide decisions on the use of various chemotherapeutic agents. Other important collaborators include Dr. Mark Bloomston, Dr. Carlo Croce, Dr. Kay Huebner, Dr. Kalpana Ghoshal, and Dr. Samson Jacobs. New antibodies have been evaluated in the research setting and several of these are now a clinically important part of our activity and include Glypican3 and B-Catenin among others. Many of our projects were presented at meetings during this time including the United States and Canadian Academy of Pathology, the American Society of Clinical Pathology, and the Society of Surgical Oncology. Some of this data has been used to submit grants for future support. Future research initiatives include expanded involvement in the Cooperative Human Tissue Network with Dr. Frankel as PI on the CHTN grant and Dr. Marsh involved in activities. The CHTN grant is a critical resource for procurement of tissue for research for many OSU and outside investigators. We continue to be active in the CALGB grant and Dr. Frankel is now the GI Pathology Cadre leader. James Liu has recently joined the GI Pathology Cadre. In addition to research activities, we have been very involved in education with medical students, residents and at the national and international level with invited lectures and short courses at the IAP, CAP, USCAP, ASCP and GI meetings.